Literature DB >> 11192476

Monitoring antiplatelet therapy: What is the best method?

D Mukherjee1, D J Moliterno.   

Abstract

Platelet function tests measure different aspects of platelet function, which include adherence, activation, aggregation and secretion. Clinically, the goal of platelet function testing is to provide information about the platelet contribution to the risk of thrombotic or haemorrhagic events and the optimisation of antiplatelet therapy. The important clinical questions are whether an antiplatelet agent is having the desired effect on platelet inhibition (effectiveness) and whether the patient has sufficient residual platelet function to avoid bleeding (safety). The role of aspirin (acetylsalicylic acid) and thienopyridines is well established in the management of patients with coronary artery disease and in the setting of coronary interventions. The last several years have demonstrated the unequivocal effectiveness of intravenously administered platelet glycoprotein (GP) IIb/IIIa antagonists in the management of acute coronary syndromes and in the setting of percutaneous coronary interventions. With the increasing use of these GPIIb/IIIa antagonists, it is becoming more important clinically to measure platelet inhibition with these agents. This paper reviews major techniques and instrumentation for platelet monitoring and discusses the goals of the best method.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192476     DOI: 10.2165/00003088-200039060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  41 in total

Review 1.  Coronary intervention and glycoprotein IIb/IIIa integrin blockade.

Authors:  M Madan; J E Tcheng
Journal:  Coron Artery Dis       Date:  1999-12       Impact factor: 1.439

Review 2.  Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.

Authors:  C M Gibson; J L Moynihan; E N Al-Mousa; M Campsey; R Gandhi; S Murphy; S Mattson; K A Ryan; R Mesley; J Swanson; M N Arshad; S J Marble
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 3.  Applications of anti-platelet monitoring in catheterization laboratory.

Authors:  D Mukherjee; D J Moliterno
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

4.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

5.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

6.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

7.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

Authors:  N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

8.  Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation.

Authors:  B S Coller; K T Springer; L E Scudder; J L Kutok; M Ceruso; G D Prestwich
Journal:  J Biol Chem       Date:  1993-10-05       Impact factor: 5.157

Review 9.  Platelet GPIIb-IIIa blockers.

Authors:  E J Topol; T V Byzova; E F Plow
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  2 in total

1.  Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.

Authors:  D Mukherjee; E Kline-Rogers; J Fang; K Munir; K A Eagle
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

2.  [Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine].

Authors:  S A Kozek-Langenecker; D Fries; M Gütl; N Hofmann; P Innerhofer; W Kneifl; L Neuner; P Perger; T Pernerstorfer; G Pfanner; H Schöchl
Journal:  Anaesthesist       Date:  2005-05       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.